Will Beta

Main Menu

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt

Will Beta

Header Banner

Will Beta

  • Volatility
  • Systematic Risk
  • Returns Of Assets
  • Beta Data
  • Finance Debt
Finance Debt
Home›Finance Debt›Co-Diagnosis: Buy the Dip? | The motley fool

Co-Diagnosis: Buy the Dip? | The motley fool

By Rogers Jennifer
May 4, 2021
0
0

Co-Diagnosis (NASDAQ: CODX) was one of the best-performing stocks of 2020, but a fourth-quarter earnings report failed to impress investment banks following the molecular diagnostics company. The stock has been under pressure since Maxim downgraded the stock to hold, and HC Wainwright nearly halved his price target on Co-Diagnostics.

Is Co-Diagnostics a good stock to buy on a downturn, or should you be cautious?

Image source: Getty Images.

The most important thing to remember about this business is that it currently relies on COVID-19 testing for almost any income. Unfortunately, cash flow from coronavirus testing has likely peaked.

Although having access to public markets since its initial public offering (Initial Public Offering) in 2017, last year was the first time that Co-Diagnostics was able to report an annual profit. After earning around $ 42 million in 2020, expectations for 2021 are significantly lower and no other diagnostic test is ready to take over.

Despite giving up around 40% of its value in the past week, Co-Diagnostics is still claiming $ 250 million market capitalization at recent prices. That’s a huge payoff for a business without a significant source of revenue to lean on once demand for COVID-19 testing falls off a cliff.

Co-Diagnostics’ proprietary technology platform is positioned to play an important role in the molecular diagnostics market, but it is a hyper-competitive industry. It’s probably best to wait and see if this business can achieve post-pandemic profitability before adding this risky stock to your portfolio.

This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.

Related posts:

  1. Capa India says second wave could lead to aviation industry collapse
  2. Apollo Global Management LLC (APO) Q1 2021 Earnings Call Transcript
  3. Is News Corporation (NWSA) a smart long-term buy?
  4. Glatfelter Reports First Quarter 2021 Results
Tagscash flowgetty images

Recent Posts

  • Racing Louisville uses transfer window to build asset base
  • Global Beta-Eudesmol Market 2022 to 2028 Growth Prospects and Key Industry Players Santa Cruz Biotechnology (SCBT), Merck KGaA (Sigma-Aldrich), AdooQ – Instant Interview
  • Saris Cycling Group, victim of the “Covid whiplash”, restructures to be sold
  • Fatigue Impacts Sexual Problems in Chinese Women With Systemic Lupus Erythematosus | BMC Women’s Health
  • Investor opinion: “Baillie Gifford taught me…

Archives

  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021

Categories

  • Beta Data
  • Finance Debt
  • Returns Of Assets
  • Systematic Risk
  • Volatility
  • Terms and Conditions
  • Privacy Policy